No abstract

A ICV é uma das principais imunodeficiências primárias de anticorpos caracterizada por redução de duas classes de imunoglobulinas e cinco fenótipos clínicos com morbidade e prognóstico heterogêneos: autoimunidade, linfoproliferação, malignidade, infecções de repetição e doença inflamatória do trato gastro intestinal. O sequenciamento total do exoma humano é método eficaz para identificar a variação genotípica e, consequentemente, o prognóstico dessa doença.

Currently, there are no evidence-based treatment options for long COVID-19, and it is known that SARS-CoV-2 can persist in part of the infected patients, especially those with immunosuppression. Since there is a robust secretion of SARS-CoV-2-specific highly-neutralizing IgA antibodies in breast milk, and because this immunoglobulin plays an essential role against respiratory virus infection in mucosa cells, being, in addition, more potent in neutralizing SARS-CoV-2 than IgG, here we report the clinical course of an NFκB-deficient patient chronically infected with the SARS-CoV-2 Gamma variant, who, after a non-full effective treatment with plasma infusion, received breast milk from a vaccinated mother by oral route as treatment for COVID-19. After such treatment, the symptoms improved, and the patient was systematically tested negative for SARS-CoV-2. Thus, we hypothesize that IgA and IgG secreted antibodies present in breast milk could be useful to treat persistent SARS-CoV-2 infection in immunodeficient patients.